Progress on Anticancer Effects of PD-1/PD-L1 Checkpoint Inhibitors
- VernacularTitle: PD-1/PD-L1免疫检查点抑制剂抗肿瘤研究进展
- Author:
Hui-Lian FAN
1
Author Information
- Publication Type:Journal Article
- Keywords: Cancer; Immune checkpoint inhibitor; Immune-related toxicity; Immunotherapy; Programmed death ligand-1(PD-L1); Programmed death-1(PD-1)
- From: Chinese Pharmaceutical Journal 2020;55(16):1321-1324
- CountryChina
- Language:Chinese
- Abstract: This artical explained the biological action mechanism of PD-1/PD-L1 monoclonal antibodies through reactivating the immune response of T cells to tumor cells immune response, analyzed the detection reports on the targets, introduced the clinical manifestations and indications research results, and looked into their development potential in the field of anticancer therapy. It's important to rationally use PD-1/PD-L1 monoclonal antibodies to decrease immune-mediated adverse events as well as maximizing the therapeutic effect. Furthermore, we should not only see the accomplishment in anticancer therapy, but also gain insight into its development direction in the field of anticancer research based on the therapeutic idea of inducing autoimmune system to kill tumor cells.
